Hepatitis Studies Shyam Kottilil M.D., Ph.D. Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Bethesda, MD
Hepatitis Studies Shyam Kottilil M.D., Ph.D. Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of.
Mar 28, 2015
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Hepatitis Studies
Shyam Kottilil M.D., Ph.D.
Laboratory of Immunoregulation
National Institute of Allergy and InfectiousDiseases
National Institutes of Health
Department of Health and Human Services
Bethesda, MD
Hepatitis C and HIV coexist in the US
0
1
2
3
4
5
Num
ber a
ffect
ed (m
illio
ns)
HCV
HIV
Sulkowski MS, Mast EE, Seeff, LB et al. Hepatitis C Virus Infection as an Opportunistic Disease in Persons infected with Human Immunodeficiency Virus. Clin Infect Dis. 2000;30:577-84.
Population
All HIV+
0
20
40
60
80
100
Perc
enta
ge
IVDU90%
33%
Population
Washington, D.C. Our Nation’s Capital
3%=18000 HIV+
1.8%=12000 HCV+
Establishment of Hepatitis Clinics
Average Incidence Rateper 100,000 Population
0 - 25.025.1 – 50.050.1 – 75.075.1 – 100.0100.1 – 125.0
Numbers found below each ward refer to the rate of newly reportedHIV cases per 100,000 population. Rates were calculated using 2000 Census data.
For 16% of cases, ward information was not available and therefore not displayed on this map.
HCV/HIVHCVHIV/HBVHBVHIV/HCV/HBV
Hepatitis Treatment Protocols-DC-PFAP
GS-7977+RBV Anti-fibrosis
Jan Mar Sept Dec Mar JuneJune Sept
HCV DAA Tx
Peg+RBV+PI (Boc) IFN and RBV FREE Tx
TLR7 PHASE 1
Anti-fibrosis
HCV-DAA
HCV-DAA
TLR7 Phase 1Natural History
Anti-fibrosis
Most Effective HIV Program
Most Effective Hepatitis Program
Washington, D.C. Our Nation’s Capital
Related Documents
